tert-butyl 4-(2-hydrazinylethyl)piperidine-1-carboxylate | 927681-15-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl 4-(2-hydrazinylethyl)piperidine-1-carboxylate
• CAS: 927681-15-0
• 化学式: C₁₂H₂₅N₃O₂
• 分子量: 243.349
• InChiKey: ALXDTCSNXWANJB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  67.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(2-hydrazinylethyl)piperidine-1-carboxylate 、 乙氧基甲叉丙二酸二乙酯 以 乙醇 为溶剂， 生成 tert-butyl 4-(2-(4-(ethoxycarbonyl)-5-hydroxy-1H-pyrazol-1-yl)ethyl)piperidine-1-carboxylate
  参考文献：
  名称：

  HETEROCYCLIC COMPOUND HAVING INHIBITORY ACTIVITY ON 11-B-HYDROXYSTEROID DEHYDROGENASE TYPE I

  摘要：

  公开号：

  EP1953145B1
• 作为产物：
  描述：

  4-(2-碘乙基)-1-哌啶羧酸叔丁酯 在 肼 作用下， 以 乙醇 为溶剂， 反应 6.5h， 生成 tert-butyl 4-(2-hydrazinylethyl)piperidine-1-carboxylate
  参考文献：
  名称：

  WO2007/24680

  摘要：

  公开号：

文献信息

• Pyrazolopyridine and pyrazolopyrimidine compounds
  申请人：Buchanan L. John

  公开号：US20070072851A1

  公开（公告）日：2007-03-29

  The present invention relates to compounds of Formula I or a stereomer, a tautomer, a solvate, a pharmaceutically acceptable salt, or a prodrug thereof, pharmaceutical formulations containing the compounds, methods of treatments using the compounds, for example, protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders and methods of preparing medicaments comprising the compounds.

  本发明涉及公式I的化合物，或其立体异构体、互变异构体、溶剂化物、药学上可接受的盐或前药，含有该化合物的制药配方，使用该化合物进行治疗的方法，例如与蛋白酪氨酸激酶相关的疾病，如免疫和肿瘤疾病，以及制备含有该化合物的药物的方法。
• Substituted pyrazolo[3,4-d]pyrimidines as ACK-1 and LCK inhibitors
  申请人：Amgen Inc.

  公开号：US07763624B2

  公开（公告）日：2010-07-27

  The present invention relates to compounds of Formula I or a stereomer, a tautomer, a solvate, a pharmaceutically acceptable salt, or a prodrug thereof, pharmaceutical formulations containing the compounds, methods of treatments using the compounds, for example, protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders and methods of preparing medicaments comprising the compounds.

  本发明涉及I式化合物或其立体异构体、互变异构体、溶剂化物、药学上可接受的盐或其前药，含有该化合物的制药组合物，使用该化合物的治疗方法，例如，蛋白酪氨酸激酶相关疾病，如免疫学和肿瘤学疾病，以及制备含有该化合物的药物的方法。
• PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS USEFUL AS KINASE ENZYMES MODULATORS
  申请人：Amgen Inc.

  公开号：EP1926734A1

  公开（公告）日：2008-06-04
• HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY
  申请人：Kurose Noriyuki

  公开号：US20090170832A1

  公开（公告）日：2009-07-02

  Disclosed is a compound useful as a type I 11βhydroxysteroid dehydrogenase inhibitor. A compound represented by the formula: a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally substituted alkyl or the like, one of R 2 and R 4 is a group of formula: —Y—R 5 , wherein Y is —O— or the like, R 5 is substituted alkyl (the substituent is optionally substituted cycloalkyl or the like), optionally substituted branched alkyl or the like, the other of R 2 and R 4 is hydrogen or optionally substituted alkyl, R 3 is a group of formula: —C(═O)-Z-R 6 , wherein Z is —NR 7 — or —NR 7 —W—, R 6 is optionally substituted cycloalkyl or the like, R 7 is hydrogen or optionally substituted alkyl, W is optionally substituted alkylene, X is ═N— or the like, with the proviso that compounds wherein R 2 is 2-(morphorino)ethoxy, R 3 is N-(1-adamantyl)carbamoyl and R 1 is benzyl are excluded.
• US7763624B2
  申请人：——

  公开号：US7763624B2

  公开（公告）日：2010-07-27